ACOG
Close Search
Menu
Home Search

ACOG Endorsed

The following documents have ACOG’s endorsement and are listed in order of endorsed date. Endorsed documents are periodically reviewed for reaffirmation.

Advertisement

Endorsement denotes that ACOG fully supports the clinical guidance in the document. Clinical documents endorsed by ACOG are considered official ACOG clinical guidance. Endorsed document hyperlinks are featured in Obstetrics & Gynecology.

Use of Language
ACOG recognizes and supports the gender diversity of all patients who seek obstetric and gynecologic care. We encourage all authors of endorsed materials to use gender-inclusive language. However, because endorsed materials include the gender terminology adopted by the authors, some endorsed materials may not fully reflect ACOG’s policy on inclusive language. See ACOG’s policy on inclusive language for more information.

2026

2024

  • AIUM-ACR-ACOG-SMFM-SRU Practice Parameter for the Performance of Standard Diagnostic Obstetric Ultrasound Examinations. American Institute of Ultrasound in Medicine, June 2024. (Endorsed June 2024)
  • Society for Maternal-Fetal Medicine Consult Series #59: The Use of Analgesia and Anesthesia for Maternal-Fetal Procedures (Endorsed September 2021, Reaffirmed February 2024)
  • Society for Maternal-Fetal Medicine Consult Series #53: Intrahepatic Cholestasis of Pregnancy (Endorsed April 2021, Reaffirmed February 2024)
  • Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America Infectious Disease Society of America, March 2019. (Endorsed April 2019, Reaffirmed February 2024)
  • Society for Maternal-Fetal Medicine Consult Series #44: Management of Bleeding in the Late Preterm Period (Endorsed March 2018, Reaffirmed February 2024)

  • National Commission on Correctional Health Care: Breastfeeding in Correctional Settings (2023) (Endorsed February 2024)

  • National Commission on Correctional Health Care: Addressing Systemic Structural and Institutional Racism in the Juvenile Legal System (2023) (Endorsed February 2024)

  • U.S Medical Eligibility Criteria for Contraceptive Use, 2024. (View PDF, View Summary Chart) Centers for Disease Control and Prevention. (Endorsed December 2024)

    Summary The 2024 U.S. Medical Eligibility Criteria for Contraceptive Use (U.S. MEC) comprises recommendations for the use of specific contraceptive methods by persons who have certain characteristics or medical conditions. These recommendations for health care providers were updated by CDC after review of the scientific evidence and a meeting with national experts in Atlanta, Georgia, during January 25–27, 2023. The information in this report replaces the 2016 U.S. MEC (CDC. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR 2016:65[No. RR-3]:1–103). Notable updates include 1) the addition of recommendations for persons with chronic kidney disease; 2) revisions to the recommendations for persons with certain characteristics or medical conditions (i.e., breastfeeding, postpartum, postabortion, obesity, surgery, deep venous thrombosis or pulmonary embolism with or without anticoagulant therapy, thrombophilia, superficial venous thrombosis, valvular heart disease, peripartum cardiomyopathy, systemic lupus erythematosus, high risk for HIV infection, cirrhosis, liver tumor, sickle cell disease, solid organ transplantation, and drug interactions with antiretrovirals used for prevention or treatment of HIV infection); and 3) inclusion of new contraceptive methods, including new doses or formulations of combined oral contraceptives, contraceptive patches, vaginal rings, progestin-only pills, levonorgestrel intrauterine devices, and vaginal pH modulator. The recommendations in this report are intended to serve as a source of evidence-based clinical practice guidance for health care providers. The goals of these recommendations are to remove unnecessary medical barriers to accessing and using contraception and to support the provision of person-centered contraceptive counseling and services in a noncoercive manner. Health care providers should always consider the individual clinical circumstances of each person seeking contraceptive services. This report is not intended to be a substitute for professional medical advice for individual patients; when needed, patients should seek advice from their health care providers about contraceptive use.

  • U.S. Selected Practice Recommendations for Contraceptive Use, 2024. (View PDF) Centers for Disease Control and Prevention. (Endorsed December 2024)

    Summary The 2024 U.S. Selected Practice Recommendations for Contraceptive Use (U.S. SPR) addresses a selected group of common, yet sometimes complex, issues regarding initiation and use of specific contraceptive methods. These recommendations for health care providers were updated by CDC after review of the scientific evidence and a meeting with national experts in Atlanta, Georgia, during January 25–27, 2023. The information in this report replaces the 2016 U.S. SPR (CDC. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR 2016;65[No. RR-4]:1–66). Notable updates include 1) updated recommendations for provision of medications for intrauterine device placement, 2) updated recommendations for bleeding irregularities during implant use, 3) new recommendations for testosterone use and risk for pregnancy, and 4) new recommendations for self-administration of injectable contraception. The recommendations in this report are intended to serve as a source of evidence based clinical practice guidance for health care providers. The goals of these recommendations are to remove unnecessary medical barriers to accessing and using contraception and to support the provision of person-centered contraceptive counseling and services in a noncoercive manner. Health care providers should always consider the individual clinical circumstances of each person seeking contraceptive services. This report is not intended to be a substitute for professional medical advice for individual patients; when needed, patients should seek advice from their health care providers about contraceptive use.

  • Recommended Adult Immunization Schedule for Ages 19 Years or Older, United States, 2025.* Centers for Disease Control and Prevention. (View PDF) (Endorsed November 2024)

*ACOG endorses the CDC's Recommended Adult Immunization Schedule for Ages 19 Years or Older, published and originally endorsed in 2024 and posted here, including the recommendation that pregnant and lactating individuals receive the COVID-19 vaccine. ACOG does not endorse the CDC's most recent recommendations, dated May 29, 2025, which has removed the COVID-19 vaccine recommendation for pregnant and lactating individuals.

  • Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2025.* Centers for Disease Control and Prevention. (View PDF) (Endorsed November 2024)

*ACOG endorses the CDC's Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, published and originally endorsed in 2024 and posted here.

2022

2021

2020

2019

2018